{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:39:21Z","timestamp":1792539561655,"version":"4.5.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"ICMR-NIMR","award":["[VBD\/NIMR\/Intra\/008-(E-OFFICE-205304) Dated 04\/11\/2024]"],"award-info":[{"award-number":["[VBD\/NIMR\/Intra\/008-(E-OFFICE-205304) Dated 04\/11\/2024]"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"DOI":"10.1007\/s15010-026-03000-9","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:01:02Z","timestamp":1792494062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging antimalarial drug targets to combat drug-resistant malaria parasites"],"prefix":"10.1007","author":[{"given":"Rohit","family":"Nehra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvashi","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Ranjha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mradul","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himmat","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Kumar","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Dhanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"3","key":"3000_CR1","doi-asserted-by":"publisher","first-page":"e1012965","DOI":"10.1371\/journal.ppat.1012965","volume":"21","author":"SA Saab","year":"2025","unstructured":"Saab SA, Cardoso-Jaime V, Kefi M, Dimopoulos G. Advances in the dissection of Anopheles\u2013Plasmodium interactions. PLoS Pathog. 2025;21:e1012965. https:\/\/doi.org\/10.1371\/journal.ppat.1012965.","journal-title":"PLoS Pathog"},{"issue":"2","key":"3000_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00203-025-04617-4","volume":"208","author":"R Nehra","year":"2026","unstructured":"Nehra R, Dhanda S, Singh K, Singh H, Bharti PK. The symbiotic Wolbachia in Anopheles and its role in reducing the transmission of Plasmodium: updates and prospects. Arch Microbiol. 2026;208:121. https:\/\/doi.org\/10.1007\/s00203-025-04617-4.","journal-title":"Arch Microbiol"},{"key":"3000_CR3","doi-asserted-by":"publisher","unstructured":"Nehra R, Kumar C, Ranjha R, Mohan M, Singh H, Bharti PK, Dhanda S. Symbiosis in Anopheles midgut microbiota: dynamics of antimicrobial resistance and modulation of Plasmodium transmission. Symbiosis. 2026. https:\/\/doi.org\/10.1007\/s13199-026-01159-1.","DOI":"10.1007\/s13199-026-01159-1"},{"key":"3000_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/ps.71077","author":"R Nehra","year":"2026","unstructured":"Nehra R, Dhanda S, Singh H, Bharti PK, Singh K. Biopesticides as an eco-friendly approach to mosquitoes and their role in reducing transmission of vector\u2010borne disease: updates and prospects. Pest Manag Sci. 2026. https:\/\/doi.org\/10.1002\/ps.71077.","journal-title":"Pest Manag Sci"},{"key":"3000_CR5","unstructured":"World Health Organization. 2025. World malaria report 2025. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2025. Accessed 28\/03\/2026."},{"key":"3000_CR6","doi-asserted-by":"publisher","first-page":"668574","DOI":"10.3389\/fgene.2021.668574","volume":"12","author":"AT Roux","year":"2021","unstructured":"Roux AT, Maharaj L, Oyegoke O, Akoniyon OP, Adeleke MA, Maharaj R, Okpeku M. Chloroquine and sulfadoxine\u2013pyrimethamine resistance in Sub-Saharan Africa\u2014a review. Front Genet. 2021;12:668574. https:\/\/doi.org\/10.3389\/fgene.2021.668574.","journal-title":"Front Genet"},{"key":"3000_CR7","doi-asserted-by":"publisher","unstructured":"Nalongo Bina K. Antimalarial drug resistance mechanisms and emerging therapeutic strategies in Plasmodium falciparum infection. https:\/\/doi.org\/10.59298\/IDOSR\/JBBAF\/2026\/10295101","DOI":"10.59298\/IDOSR\/JBBAF\/2026\/10295101"},{"issue":"2","key":"3000_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1021\/acs.jmedchem.3c01828","volume":"67","author":"PM Cheuka","year":"2024","unstructured":"Cheuka PM, Njaria P, Mayoka G, Funjika E. Emerging drug targets for antimalarial drug discovery: validation and insights into molecular mechanisms of function. J Med Chem. 2024;67:838\u201363. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01828.","journal-title":"J Med Chem"},{"key":"3000_CR9","doi-asserted-by":"publisher","unstructured":"Gashema P, Kagame J, Iradukunda PG, Siddig EE, Tessema SK, Tegegne MA, Muvunyi CM. Mapping Plasmodium falciparum mutations in Africa: a critical review of emerging drug resistance and implications for malaria control. Int J Infect Dis. 2025;108033. https:\/\/doi.org\/10.1016\/j.ijid.2025.108033.","DOI":"10.1016\/j.ijid.2025.108033"},{"key":"3000_CR10","doi-asserted-by":"publisher","first-page":"e66277","DOI":"10.7554\/eLife.66277","volume":"10","author":"BH Stokes","year":"2021","unstructured":"Stokes BH, Dhingra SK, Rubiano K, Mok S, Straimer J, Gn\u00e4dig NF, Fidock DA. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. Elife. 2021;10:e66277. https:\/\/doi.org\/10.7554\/eLife.66277.","journal-title":"Elife"},{"issue":"5","key":"3000_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/bfgp\/elz008","volume":"18","author":"AN Cowell","year":"2019","unstructured":"Cowell AN, Winzeler EA. The genomic architecture of antimalarial drug resistance. Brief Funct Genomics. 2019;18:314\u201328. https:\/\/doi.org\/10.1093\/bfgp\/elz008.","journal-title":"Brief Funct Genomics"},{"issue":"1","key":"3000_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12936-019-2853-4","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Saidi Q, Sibley CH, Roper C, Alifrangis M. Deployment and utilization of next-generation sequencing of Plasmodium falciparum to guide anti-malarial drug policy decisions in sub-Saharan Africa: opportunities and challenges. Malar J. 2019;18:267. https:\/\/doi.org\/10.1186\/s12936-019-2853-4.","journal-title":"Malar J"},{"issue":"8","key":"3000_CR13","doi-asserted-by":"publisher","first-page":"e0256343","DOI":"10.1371\/journal.pone.0256343","volume":"16","author":"AGB Tuedom","year":"2021","unstructured":"Tuedom AGB, Sarah-Matio EM, Moukoko CEE, Feufack-Donfack BL, Maffo CN, Bayibeki AN, Nsango SE. Antimalarial drug resistance in the Central and Adamawa regions of cameroon: prevalence of mutations in P. falciparum crt, Pfmdr1, Pfdhfr and Pfdhps genes. PLoS ONE. 2021;16:e0256343. https:\/\/doi.org\/10.1371\/journal.pone.0256343.","journal-title":"PLoS ONE"},{"issue":"2","key":"3000_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/bab.70040","volume":"73","author":"K Verma","year":"2026","unstructured":"Verma K, Patel K, Yadav A, Gopikrishnan M, Sharma R, Mohan M, Bharti PK. Computational drug repositioning for targeting pfEMP1: potential therapeutics for cerebral malaria in plasmodium falciparum. Biotechnol Appl Chem. 2026;73:488\u2013512. https:\/\/doi.org\/10.1002\/bab.70040.","journal-title":"Biotechnol Appl Chem"},{"issue":"4","key":"3000_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.4269\/ajtmh.2011.11-0108","volume":"85","author":"C Setthaudom","year":"2011","unstructured":"Setthaudom C, Tan-Ariya P, Sitthichot N, Khositnithikul R, Suwandittakul N, Leelayoova S, Mungthin M. Role of Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes on in vitro chloroquine resistance in isolates of Plasmodium falciparum from Thailand. Am J Trop Med Hyg. 2011;85:606. https:\/\/doi.org\/10.4269\/ajtmh.2011.11-0108.","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"3000_CR16","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/jac\/dky258","volume":"73","author":"P Nkoli Mandoko","year":"2018","unstructured":"Nkoli Mandoko P, Rouvier F, Kakina M, Moke Mbongi L, Latour D, Likwela CL, J., et al. Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine\/pyrimethamine in the Democratic Republic of the Congo: emergence of highly resistant pfdhfr\/pfdhps alleles. J Antimicrob Chemother. 2018;73:2704\u201315. https:\/\/doi.org\/10.1093\/jac\/dky258.","journal-title":"J Antimicrob Chemother"},{"key":"3000_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpddr.2019.11.002","volume":"12","author":"L Zhao","year":"2020","unstructured":"Zhao L, Pi L, Qin Y, Lu Y, Zeng W, Xiang Z, et al. Widespread resistance mutations to sulfadoxine-pyrimethamine in malaria parasites imported to China from Central and Western Africa. Int J Parasitology: Drugs Drug Resist. 2020;12:1\u20136. https:\/\/doi.org\/10.1016\/j.ijpddr.2019.11.002.","journal-title":"Int J Parasitology: Drugs Drug Resist"},{"issue":"11","key":"3000_CR18","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1073\/pnas.1913525117","volume":"117","author":"KY Lu","year":"2020","unstructured":"Lu KY, Quan B, Sylvester K, Srivastava T, Fitzgerald MC, Derbyshire ER. Plasmodium chaperonin TRiC\/CCT identified as a target of the antihistamine clemastine using parallel chemoproteomic strategy. Proc Natl Acad Sci. 2020;117:5810\u20137. https:\/\/doi.org\/10.1073\/pnas.1913525117.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"3000_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1021\/acs.biochem.9b01105","volume":"59","author":"KY Lu","year":"2020","unstructured":"Lu KY, Derbyshire ER. Tafenoquine: a step toward malaria elimination. Biochemistry. 2020;59:911. https:\/\/doi.org\/10.1021\/acs.biochem.9b01105.","journal-title":"Biochemistry"},{"issue":"1","key":"3000_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12936-024-04848-8","volume":"23","author":"A Assefa","year":"2024","unstructured":"Assefa A, Fola AA, Tasew G. Emergence of Plasmodium falciparum strains with artemisinin partial resistance in East Africa and the Horn of Africa: is there a need to panic? Malar J. 2024;23:34. https:\/\/doi.org\/10.1186\/s12936-024-04848-8.","journal-title":"Malar J"},{"key":"3000_CR21","doi-asserted-by":"publisher","first-page":"100602","DOI":"10.1016\/j.ijpddr.2025.100602","volume":"28","author":"L Theodoridis","year":"2025","unstructured":"Theodoridis L, Carvalho TG. Antimalarial drug resistance and drug discovery: learning from the past to innovate the future. Int J Parasitology: Drugs Drug Resist. 2025;28:100602. https:\/\/doi.org\/10.1016\/j.ijpddr.2025.100602.","journal-title":"Int J Parasitology: Drugs Drug Resist"},{"issue":"5948","key":"3000_CR22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1126\/science.1175667","volume":"325","author":"RE Martin","year":"2009","unstructured":"Martin RE, Marchetti RV, Cowan AI, Howitt SM, Br\u00f6er S, Kirk K. Chloroquine transport via the malaria parasite\u2019s chloroquine resistance transporter. Science. 2009;325:1680\u20132.","journal-title":"Science"},{"issue":"4","key":"3000_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","volume":"91","author":"M Venkatesan","year":"2014","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"3000_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/1475-2875-10-351","volume":"10","author":"D Fernando","year":"2011","unstructured":"Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:351.","journal-title":"Malar J"},{"issue":"3","key":"3000_CR25","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1093\/cid\/ciac728","volume":"76","author":"CM Thomas","year":"2023","unstructured":"Thomas CM, Stauffer WM, Alpern JD. Food and drug administration approval of artesunate for severe malaria: enough to achieve best practice? Clin Infect Dis. 2023;76:e864\u20136.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3000_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/pharmaceutics14030504","volume":"14","author":"N Ruwizhi","year":"2022","unstructured":"Ruwizhi N, Maseko RB, Aderibigbe BA. Recent advances in the therapeutic efficacy of artesunate. Pharmaceutics. 2022;14:504.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3000_CR27","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1073\/pnas.91.3.1143","volume":"91","author":"AF Cowman","year":"1994","unstructured":"Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci. 1994;91:1143\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"5591","key":"3000_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1126\/science.1074045","volume":"298","author":"ABS Sidhu","year":"2002","unstructured":"Sidhu ABS, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002;298:210\u20133.","journal-title":"Science"},{"issue":"9","key":"3000_CR29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40265-018-0911-9","volume":"78","author":"EA Ashley","year":"2018","unstructured":"Ashley EA, Phyo AP. Drugs in development for Malaria: EA Ashley, AP Phyo. Drugs. 2018;78:861\u201379.","journal-title":"Drugs"},{"key":"3000_CR30","doi-asserted-by":"crossref","unstructured":"Styka AN, Savitz DA, editors. (2020). Assessment of long-term health effects of antimalarial drugs when used for prophylaxis.","DOI":"10.17226\/25688"},{"issue":"S1","key":"3000_CR31","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1093\/jtm\/6.suppl.S8","volume":"6","author":"M Pudney","year":"1999","unstructured":"Pudney M, Gutteridge W, Zeman A, Dickins M, Woolley JL. Atovaquone and proguanil hydrochloride: a review of nonclinical studies. J Travel Med. 1999;6:S8\u201312.","journal-title":"J Travel Med"},{"issue":"14","key":"3000_CR32","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ijpara.2006.07.011","volume":"36","author":"J Golenser","year":"2006","unstructured":"Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol. 2006;36:1427\u201341.","journal-title":"Int J Parasitol"},{"issue":"10","key":"3000_CR33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","volume":"22","author":"JL Siqueira-Neto","year":"2023","unstructured":"Siqueira-Neto JL, Wicht KJ, Chibale K, Burrows JN, Fidock DA, Winzeler EA. Antimalarial drug discovery: progress and approaches. Nat Rev Drug Discovery. 2023;22:807\u201326. https:\/\/doi.org\/10.1038\/s41573-023-00772-9.","journal-title":"Nat Rev Drug Discovery"},{"issue":"6","key":"3000_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cmi.2025.03.009","volume":"31","author":"DG Okwu","year":"2025","unstructured":"Okwu DG, Manego RZ, Duparc S, Kremsner PG, Ramharter M, Mombo-Ngoma G. The non-artemisinin antimalarial drugs under development: a review. Clin Microbiol Infect. 2025;31:941\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2025.03.009.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"3000_CR35","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/pharmaceutics13122189","volume":"13","author":"A Guasch-Girbau","year":"2021","unstructured":"Guasch-Girbau A, Fern\u00e0ndez-Busquets X. Review of the current landscape of the potential of nanotechnology for future malaria diagnosis, treatment, and vaccination strategies. Pharmaceutics. 2021;13:2189. https:\/\/doi.org\/10.3390\/pharmaceutics13122189.","journal-title":"Pharmaceutics"},{"issue":"9","key":"3000_CR36","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/psp4.13013","volume":"12","author":"N Abla","year":"2023","unstructured":"Abla N, Howgate E, Rowland-Yeo K, Dickins M, Bergagnini\u2010Kolev MC, Chen KF, et al. Development and application of a PBPK modeling strategy to support antimalarial drug development. CPT: Pharmacometrics Syst Pharmacol. 2023;12:1335\u201346. https:\/\/doi.org\/10.1002\/psp4.13013.","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"3000_CR37","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/pharmaceutics15071800","volume":"15","author":"H Alaithan","year":"2023","unstructured":"Alaithan H, Kumar N, Islam MZ, Liappis AP, Nava VE. Novel therapeutics for malaria. Pharmaceutics. 2023;15:1800. https:\/\/doi.org\/10.3390\/pharmaceutics15071800.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3000_CR38","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1038\/s41467-023-41119-7","volume":"14","author":"D Rodr\u00edguez-Hern\u00e1ndez","year":"2023","unstructured":"Rodr\u00edguez-Hern\u00e1ndez D, Vijayan K, Zigweid R, Fenwick MK, Sankaran B, Roobsoong W, et al. Identification of potent and selective N-myristoyltransferase inhibitors of Plasmodium vivax liver stage hypnozoites and schizonts. Nat Commun. 2023;14:5408. https:\/\/doi.org\/10.1038\/s41467-023-41119-7.","journal-title":"Nat Commun"},{"key":"3000_CR39","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.1016\/j.dcit.2025.100064","volume":"3","author":"N Tan","year":"2025","unstructured":"Tan N, Gao Y, Xu W, Liu T. Current therapies and advances in the development pipeline of pre-erythrocytic preventive drugs. Decoding Infect Transmission. 2025;3:100064. https:\/\/doi.org\/10.1016\/j.dcit.2025.100064.","journal-title":"Decoding Infect Transmission"},{"issue":"1","key":"3000_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","volume":"16","author":"JN Burrows","year":"2017","unstructured":"Burrows JN, Duparc S, Gutteridge WE, van Hooft R, Kaszubska W, Macintyre F, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16:26. https:\/\/doi.org\/10.1186\/s12936-016-1675-x.","journal-title":"Malar J"},{"key":"3000_CR41","doi-asserted-by":"publisher","first-page":"1057232","DOI":"10.3389\/fmolb.2022.1057232","volume":"9","author":"MD Wilkinson","year":"2022","unstructured":"Wilkinson MD, Ferreira JL, Beeby M, Baum J, Willison KR. The malaria parasite chaperonin containing TCP-1 (CCT) complex: data integration with other CCT proteomes. Front Mol Biosci. 2022;9:1057232. https:\/\/doi.org\/10.3389\/fmolb.2022.1057232.","journal-title":"Front Mol Biosci"},{"key":"3000_CR42","doi-asserted-by":"publisher","first-page":"1308193","DOI":"10.3389\/fcimb.2023.1308193","volume":"13","author":"AP Luo","year":"2023","unstructured":"Luo AP, Giannangelo C, Siddiqui G, Creek DJ. Promising antimalarial hits from phenotypic screens: a review of recently-described multi-stage actives and their modes of action. Front Cell Infect Microbiol. 2023;13:1308193. https:\/\/doi.org\/10.3389\/fcimb.2023.1308193.","journal-title":"Front Cell Infect Microbiol"},{"key":"3000_CR43","doi-asserted-by":"publisher","first-page":"102220","DOI":"10.1016\/j.mib.2022.102220","volume":"70","author":"F Guerra","year":"2022","unstructured":"Guerra F, Winzeler EA. New targets for antimalarial drug discovery. Curr Opin Microbiol. 2022;70:102220. https:\/\/doi.org\/10.1016\/j.mib.2022.102220","journal-title":"Curr Opin Microbiol"},{"issue":"1","key":"3000_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12936-019-2665-6","volume":"18","author":"DW Nyamai","year":"2019","unstructured":"Nyamai DW, Tastan Bishop \u00d6. Aminoacyl tRNA synthetases as malarial drug targets: a comparative bioinformatics study. Malar J. 2019;18:34. https:\/\/doi.org\/10.1186\/s12936-019-2665-6.","journal-title":"Malar J"},{"issue":"7","key":"3000_CR45","doi-asserted-by":"publisher","first-page":"e1013057","DOI":"10.1371\/journal.ppat.1013057","volume":"21","author":"N Ketprasit","year":"2025","unstructured":"Ketprasit N, Tai CW, Sharma VK, Manickam Y, Khandokar Y, Ye X, et al. Natural product-mediated reaction hijacking mechanism validates Plasmodium aspartyl-tRNA synthetase as an antimalarial drug target. PLoS Pathog. 2025;21:e1013057. https:\/\/doi.org\/10.1371\/journal.ppat.1013057.","journal-title":"PLoS Pathog"},{"issue":"686","key":"3000_CR46","doi-asserted-by":"publisher","first-page":"eadc9249","DOI":"10.1126\/scitranslmed.adc9249","volume":"15","author":"ES Istvan","year":"2023","unstructured":"Istvan ES, Guerra F, Abraham M, Huang KS, Rocamora F, Zhao H, et al. Cytoplasmic isoleucyl tRNA synthetase as an attractive multistage antimalarial drug target. Sci Transl Med. 2023;15:eadc9249. https:\/\/doi.org\/10.1126\/scitranslmed.adc9249.","journal-title":"Sci Transl Med"},{"key":"3000_CR47","doi-asserted-by":"publisher","unstructured":"Hamami SMA, Riswana FR, Fitri LE, Widodo N, Zakaria MNZ, Aththar AF, et al. In Silico Screening of Streptomyces sp. Metabolites Targeting P. falciparum DHODH and DPCK for Antimalarial Discovery. Biol Targets Ther. 2025. https:\/\/doi.org\/10.2147\/BTT.S539147.","DOI":"10.2147\/BTT.S539147"},{"issue":"4","key":"3000_CR48","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3390\/ijms22041750","volume":"22","author":"L Pang","year":"2021","unstructured":"Pang L, Weeks SD, Van Aerschot A. Aminoacyl-tRNA synthetases as valuable targets for antimicrobial drug discovery. Int J Mol Sci. 2021;22:1750. https:\/\/doi.org\/10.3390\/ijms22041750.","journal-title":"Int J Mol Sci"},{"key":"3000_CR49","doi-asserted-by":"publisher","DOI":"10.2147\/RRBC.S83482","author":"S Chakraborty","year":"2016","unstructured":"Chakraborty S, Banerjee R Phenylalanyl-tRNA synthetase. Res Rep Biochem. 2016. https:\/\/doi.org\/10.2147\/RRBC.S83482.","journal-title":"Res Rep Biochem"},{"issue":"11","key":"3000_CR50","doi-asserted-by":"publisher","first-page":"EMBJ2021109985","DOI":"10.15252\/embj.2021109985","volume":"41","author":"AP Pitera","year":"2022","unstructured":"Pitera AP, Szaruga M, Peak-Chew SY, Wingett SW, Bertolotti A. Cellular responses to halofuginone reveal a vulnerability of the GCN2 branch of the integrated stress response. EMBO J. 2022;41:EMBJ2021109985. https:\/\/doi.org\/10.15252\/embj.2021109985.","journal-title":"EMBO J"},{"issue":"1","key":"3000_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12936-016-1247-0","volume":"15","author":"S Khan","year":"2016","unstructured":"Khan S. Recent advances in the biology and drug targeting of malaria parasite aminoacyl-tRNA synthetases. Malar J. 2016;15:203. https:\/\/doi.org\/10.1186\/s12936-016-1247-0.","journal-title":"Malar J"},{"issue":"1","key":"3000_CR52","doi-asserted-by":"publisher","first-page":"2640718","DOI":"10.1080\/14756366.2026.2640718","volume":"41","author":"C Tambascia","year":"2026","unstructured":"Tambascia C, Silva JC, Reis D, Camilo BC, Junior CFST, Hancio CA, T., et al. Inhibition of prolyl-tRNA synthetase and efflux pumps as a dual-targeting strategy against multidrug-resistant bacteria. J Enzyme Inhib Med Chem. 2026;41:2640718. https:\/\/doi.org\/10.1080\/14756366.2026.2640718.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"11","key":"3000_CR53","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.3390\/ijms21113803","volume":"21","author":"DW Nyamai","year":"2020","unstructured":"Nyamai DW, Tastan Bishop \u00d6. Identification of selective novel hits against plasmodium falciparum prolyl tRNA synthetase active site and a predicted allosteric site using in silico approaches. Int J Mol Sci. 2020;21:3803. https:\/\/doi.org\/10.3390\/ijms21113803.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3000_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev-micro-032421-121210","volume":"77","author":"SC Xie","year":"2023","unstructured":"Xie SC, Griffin MD, Winzeler EA, Ribas de Pouplana L, Tilley L. Targeting aminoacyl tRNA synthetases for antimalarial drug development. Annu Rev Microbiol. 2023;77:111\u201329. https:\/\/doi.org\/10.1146\/annurev-micro-032421-121210.","journal-title":"Annu Rev Microbiol"},{"issue":"8","key":"3000_CR55","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.bmcl.2013.02.075","volume":"23","author":"A Sugawara","year":"2013","unstructured":"Sugawara A, Tanaka T, Hirose T, Ishiyama A, Iwatsuki M, Takahashi Y, et al. Borrelidin analogues with antimalarial activity: design, synthesis and biological evaluation against Plasmodium falciparum parasites. Bioorg Med Chem Lett. 2013;23:2302\u20135. https:\/\/doi.org\/10.1016\/j.bmcl.2013.02.075.","journal-title":"Bioorg Med Chem Lett"},{"key":"3000_CR56","doi-asserted-by":"publisher","first-page":"100548","DOI":"10.1016\/j.ijpddr.2024.100548","volume":"25","author":"F Olotu","year":"2024","unstructured":"Olotu F, Tali MBT, Chepsiror C, Amamuddy OS, Boyom FF, Bishop \u00d6T. Repurposing DrugBank compounds as potential Plasmodium falciparum class 1a aminoacyl tRNA synthetase multi-stage pan-inhibitors with a specific focus on mitomycin. Int J Parasitology: Drugs Drug Resist. 2024;25:100548. https:\/\/doi.org\/10.1016\/j.ijpddr.2024.100548.","journal-title":"Int J Parasitology: Drugs Drug Resist"},{"issue":"14","key":"3000_CR57","doi-asserted-by":"publisher","first-page":"e70401","DOI":"10.1002\/cmdc.70401","volume":"21","author":"SYM Lim","year":"2026","unstructured":"Lim SYM. Aminopeptidase inhibition in drug-resistant Plasmodium falciparum: structural, functional, and pharmacological rationale for targeting PfA\u2010M1 and PfA\u2010M17. ChemMedChem. 2026;21:e70401. https:\/\/doi.org\/10.1002\/cmdc.70401.","journal-title":"ChemMedChem"},{"issue":"1","key":"3000_CR58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12936-025-05518-z","volume":"24","author":"G Niramolyanun","year":"2025","unstructured":"Niramolyanun G, Praikongkatham C, Jenwithisuk R, Roobsoong W, Sattabongkot J, Pankao V, Kangwanrangsan N. Aspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte development. Malar J. 2025;24:271. https:\/\/doi.org\/10.1186\/s12936-025-05518-z.","journal-title":"Malar J"},{"key":"3000_CR59","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fmicb.2019.00394","volume":"10","author":"M Mishra","year":"2019","unstructured":"Mishra M, Singh V, Singh S. Structural insights into key Plasmodium proteases as therapeutic drug targets. Front Microbiol. 2019;10:394. https:\/\/doi.org\/10.3389\/fmicb.2019.00394.","journal-title":"Front Microbiol"},{"issue":"25","key":"3000_CR60","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1074\/jbc.REV120.009309","volume":"295","author":"AS Nasamu","year":"2020","unstructured":"Nasamu AS, Polino AJ, Istvan ES, Goldberg DE. Malaria parasite plasmepsins: more than just plain old degradative pepsins. J Biol Chem. 2020;295:8425\u201341. https:\/\/doi.org\/10.1074\/jbc.REV120.009309.","journal-title":"J Biol Chem"},{"issue":"2","key":"3000_CR61","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1073\/pnas.022630099","volume":"99","author":"R Banerjee","year":"2002","unstructured":"Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci. 2002;99:990\u20135. https:\/\/doi.org\/10.1073\/pnas.022630099.","journal-title":"Proc Natl Acad Sci"},{"issue":"6362","key":"3000_CR62","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1126\/science.aaf8675","volume":"358","author":"P Pino","year":"2017","unstructured":"Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, et al. A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. Science. 2017;358:522\u20138. https:\/\/doi.org\/10.1126\/science.aaf8675.","journal-title":"Science"},{"key":"3000_CR63","doi-asserted-by":"publisher","first-page":"850176","DOI":"10.3389\/fphar.2022.850176","volume":"13","author":"A Uddin","year":"2022","unstructured":"Uddin A, Gupta S, Mohammad T, Shahi D, Hussain A, Alajmi MF, et al. Target-based virtual screening of natural compounds identifies a potent antimalarial with selective falcipain-2 inhibitory activity. Front Pharmacol. 2022;13:850176. https:\/\/doi.org\/10.3389\/fphar.2022.850176.","journal-title":"Front Pharmacol"},{"issue":"11","key":"3000_CR64","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1021\/acs.accounts.1c00154","volume":"54","author":"KA de Villiers","year":"2021","unstructured":"de Villiers KA, Egan TJ. Heme detoxification in the malaria parasite: A target for antimalarial drug development. Acc Chem Res. 2021;54:2649. https:\/\/doi.org\/10.1021\/acs.accounts.1c00154.","journal-title":"Acc Chem Res"},{"issue":"1","key":"3000_CR65","doi-asserted-by":"publisher","first-page":"10111","DOI":"10.1038\/ncomms10111","volume":"6","author":"J Wang","year":"2015","unstructured":"Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111. https:\/\/doi.org\/10.1038\/ncomms10111.","journal-title":"Nat Commun"},{"issue":"3","key":"3000_CR66","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/infdis\/jiy188","volume":"218","author":"FA Siddiqui","year":"2018","unstructured":"Siddiqui FA, Cabrera M, Wang M, Brashear A, Kemirembe K, Wang Z, et al. Plasmodium falciparum falcipain-2a polymorphisms in Southeast Asia and their association with artemisinin resistance. J Infect Dis. 2018;218:434\u201342. https:\/\/doi.org\/10.1093\/infdis\/jiy188.","journal-title":"J Infect Dis"},{"issue":"1","key":"3000_CR67","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022;13:6353. https:\/\/doi.org\/10.1038\/s41467-022-33873-x.","journal-title":"Nat Commun"},{"issue":"28","key":"3000_CR68","doi-asserted-by":"publisher","first-page":"16546","DOI":"10.1073\/pnas.2001153117","volume":"117","author":"JM Matz","year":"2020","unstructured":"Matz JM, Drepper B, Blum TB, van Genderen E, Burrell A, Martin P, et al. A lipocalin mediates unidirectional heme biomineralization in malaria parasites. Proc Natl Acad Sci. 2020;117:16546\u201356. https:\/\/doi.org\/10.1073\/pnas.2001153117.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"3000_CR69","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1128\/AAC.01167-10","volume":"55","author":"AM Lehane","year":"2011","unstructured":"Lehane AM, Van Schalkwyk DA, Valderramos SG, Fidock DA, Kirk K. Differential drug efflux or accumulation does not explain variation in the chloroquine response of Plasmodium falciparum strains expressing the same isoform of mutant PfCRT. Antimicrob Agents Chemother. 2011;55:2310\u20138. https:\/\/doi.org\/10.1128\/AAC.01167-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3000_CR70","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1128\/aac.01739-10","volume":"55","author":"K Slavic","year":"2011","unstructured":"Slavic K, Delves MJ, Prud\u00eancio M, Talman AM, Straschil U, Derbyshire ET, et al. Use of a selective inhibitor to define the chemotherapeutic potential of the plasmodial hexose transporter in different stages of the parasite\u2019s life cycle. Antimicrob Agents Chemother. 2011;55:2824\u201330. https:\/\/doi.org\/10.1128\/aac.01739-10.","journal-title":"Antimicrob Agents Chemother"},{"key":"3000_CR71","doi-asserted-by":"publisher","DOI":"10.2147\/idr.s279433","author":"MA Shibeshi","year":"2020","unstructured":"Shibeshi MA, Kifle ZD, Atnafie SA Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 2020. https:\/\/doi.org\/10.2147\/idr.s279433.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"3000_CR72","doi-asserted-by":"publisher","first-page":"e2017749118","DOI":"10.1073\/pnas.2017749118","volume":"118","author":"J Huang","year":"2021","unstructured":"Huang J, Yuan Y, Zhao N, Pu D, Tang Q, Zhang S, et al. Orthosteric\u2013allosteric dual inhibitors of PfHT1 as selective antimalarial agents. Proc Natl Acad Sci. 2021;118:e2017749118. https:\/\/doi.org\/10.1073\/pnas.2017749118.","journal-title":"Proc Natl Acad Sci"},{"key":"3000_CR73","doi-asserted-by":"publisher","first-page":"1321240","DOI":"10.3389\/fcimb.2023.1321240","volume":"13","author":"JY Won","year":"2024","unstructured":"Won JY, Mazigo E, Cha SH, Han JH. Functional characterization of Plasmodium vivax hexose transporter 1. Front Cell Infect Microbiol. 2024;13:1321240. https:\/\/doi.org\/10.3389\/fcimb.2023.1321240.","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"3000_CR74","doi-asserted-by":"publisher","first-page":"e0268269","DOI":"10.1371\/journal.pone.0268269","volume":"17","author":"AJ Owoloye","year":"2022","unstructured":"Owoloye AJ, Ligali FC, Enejoh OA, Musa AZ, Aina O, Idowu ET, Oyebola KM. Molecular docking, simulation and binding free energy analysis of small molecules as Pf HT1 inhibitors. PLoS ONE. 2022;17:e0268269. https:\/\/doi.org\/10.1371\/journal.pone.0268269.","journal-title":"PLoS ONE"},{"issue":"23","key":"3000_CR75","doi-asserted-by":"publisher","first-page":"14450","DOI":"10.1080\/07391102.2023.2181635","volume":"41","author":"A Altharawi","year":"2023","unstructured":"Altharawi A, Riadi Y, Tahir ul, Qamar M. An in silico quest for next-generation antimalarial drugs by targeting Plasmodium falciparum hexose transporter protein: a multi-pronged approach. J Biomol Struct Dynamics. 2023;41:14450\u20139. https:\/\/doi.org\/10.1080\/07391102.2023.2181635.","journal-title":"J Biomol Struct Dynamics"},{"issue":"1","key":"3000_CR76","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41598-020-80658-7","volume":"11","author":"RK Sah","year":"2021","unstructured":"Sah RK, Pati S, Saini M, Singh S. Erythrocyte sphingosine kinase regulates intraerythrocytic development of Plasmodium falciparum. Sci Rep. 2021;11:1257. https:\/\/doi.org\/10.1038\/s41598-020-80658-7.","journal-title":"Sci Rep"},{"issue":"1","key":"3000_CR77","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1038\/ncomms7284","volume":"6","author":"B Wu","year":"2015","unstructured":"Wu B, Rambow J, Bock S, Holm-Bertelsen J, Wiechert M, Soares AB, et al. Identity of a Plasmodium lactate\/H+ symporter structurally unrelated to human transporters. Nat Commun. 2015;6:6284. https:\/\/doi.org\/10.1038\/ncomms7284.","journal-title":"Nat Commun"},{"issue":"8","key":"3000_CR78","doi-asserted-by":"publisher","first-page":"e00356","DOI":"10.1128\/aac.00356-23","volume":"67","author":"H Davies","year":"2023","unstructured":"Davies H, Bergmann B, Walloch P, Nerlich C, Hansen C, Wittlin S, et al. The Plasmodium lactate\/H+ transporter PfFNT is essential and druggable in vivo. Antimicrob Agents Chemother. 2023;67:e00356\u201323. https:\/\/doi.org\/10.1128\/aac.00356-23.","journal-title":"Antimicrob Agents Chemother"},{"issue":"20","key":"3000_CR79","doi-asserted-by":"publisher","first-page":"18368","DOI":"10.1021\/acs.jmedchem.4c01674","volume":"67","author":"C Nerlich","year":"2024","unstructured":"Nerlich C, Tiedjens F, Hertel R, Henke B, H\u00e4uer S, Panitzsch LS, et al. Addressing the intracellular vestibule of the plasmodial lactate transporter PfFNT by p-substituted inhibitors amplifies in vitro activity. J Med Chem. 2024;67:18368\u201383. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01674.","journal-title":"J Med Chem"},{"issue":"2","key":"3000_CR80","doi-asserted-by":"publisher","first-page":"e1006180","DOI":"10.1371\/journal.ppat.1006180","volume":"13","author":"SV Hapuarachchi","year":"2017","unstructured":"Hapuarachchi SV, Cobbold SA, Shafik SH, Dennis AS, McConville MJ, Martin RE, et al. The malaria parasite\u2019s lactate transporter PfFNT is the target of antiplasmodial compounds identified in whole cell phenotypic screens. PLoS Pathog. 2017;13:e1006180. https:\/\/doi.org\/10.1371\/journal.ppat.1006180.","journal-title":"PLoS Pathog"},{"issue":"10","key":"3000_CR81","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.00771-21","volume":"65","author":"O Kreutzfeld","year":"2021","unstructured":"Kreutzfeld O, Rasmussen SA, Ramanathan AA, Tumwebaze PK, Byaruhanga O, Katairo T, et al. Associations between varied susceptibilities to PfATP4 inhibitors and genotypes in Ugandan Plasmodium falciparum isolates. Antimicrob Agents Chemother. 2021;65:10\u20131128. https:\/\/doi.org\/10.1128\/aac.00771-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3000_CR82","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1021\/acsinfecdis.3c00588","volume":"10","author":"JC Lindblom","year":"2024","unstructured":"Lindblom JC, Zhang X, Lehane AM. A pH fingerprint assay to identify inhibitors of multiple validated and potential antimalarial drug targets. ACS Infect Dis. 2024;10:1185. https:\/\/doi.org\/10.1021\/acsinfecdis.3c00588.","journal-title":"ACS Infect Dis"},{"issue":"1","key":"3000_CR83","doi-asserted-by":"publisher","first-page":"9092","DOI":"10.1038\/s41467-025-64815-y","volume":"16","author":"MT Haile","year":"2025","unstructured":"Haile MT, Shukla A, Zhen J, Mather MW, Bhatnagar S, Morrisey JM, et al. Endogenous structure of antimalarial target Pf ATP4 reveals an apicomplexan-specific P-type ATPase modulator. Nat Commun. 2025;16:9092. https:\/\/doi.org\/10.1038\/s41467-025-64815-y.","journal-title":"Nat Commun"},{"key":"3000_CR84","doi-asserted-by":"publisher","first-page":"708834","DOI":"10.3389\/fcimb.2021.708834","volume":"11","author":"LS de Oliveira","year":"2021","unstructured":"de Oliveira LS, Alborghetti MR, Carneiro RG, Bastos IMD, Amino R, Grellier P, Charneau S. Calcium in the backstage of malaria parasite biology. Front Cell Infect Microbiol. 2021;11:708834. https:\/\/doi.org\/10.3389\/fcimb.2021.708834.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"3000_CR85","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.1038\/ncomms6521","volume":"5","author":"AB Vaidya","year":"2014","unstructured":"Vaidya AB, Morrisey JM, Zhang Z, Das S, Daly TM, Otto TD, et al. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nat Commun. 2014;5:5521. https:\/\/doi.org\/10.1038\/ncomms6521.","journal-title":"Nat Commun"},{"issue":"2","key":"3000_CR86","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1021\/cb500616x","volume":"10","author":"EL Flannery","year":"2015","unstructured":"Flannery EL, McNamara CW, Kim SW, Kato TS, Li F, Teng CH, et al. Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. ACS Chem Biol. 2015;10:413\u201320. https:\/\/doi.org\/10.1021\/cb500616x.","journal-title":"ACS Chem Biol"},{"issue":"6","key":"3000_CR87","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00087-18","volume":"62","author":"AS Dennis","year":"2018","unstructured":"Dennis AS, Lehane AM, Ridgway MC, Holleran JP, Kirk K. Cell swelling induced by the antimalarial KAE609 (cipargamin) and other PfATP4-associated antimalarials. Antimicrob Agents Chemother. 2018;62:10\u20131128. https:\/\/doi.org\/10.1128\/AAC.00087-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"3000_CR88","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/s1471-4922(02)02350-4","volume":"18","author":"H Ginsburg","year":"2002","unstructured":"Ginsburg H. Abundant proton pumping in Plasmodium, but why? Trends Parasitol. 2002;18:483\u20136. https:\/\/doi.org\/10.1016\/s1471-4922(02)02350-4.","journal-title":"Trends Parasitol"},{"issue":"2","key":"3000_CR89","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.chom.2012.12.006","volume":"13","author":"NJ Spillman","year":"2013","unstructured":"Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K. Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe. 2013;13:227\u201337. https:\/\/doi.org\/10.1016\/j.chom.2012.12.006.","journal-title":"Cell Host Microbe"},{"issue":"10","key":"3000_CR90","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.3390\/cells9102225","volume":"9","author":"CF Dick","year":"2020","unstructured":"Dick CF, Meyer-Fernandes JR, Vieyra A. The functioning of Na+-ATPases from Protozoan Parasites: are these pumps targets for antiparasitic drugs? Cells. 2020;9:2225. https:\/\/doi.org\/10.3390\/cells9102225.","journal-title":"Cells"},{"issue":"2","key":"3000_CR91","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/14728222.2023.2185511","volume":"27","author":"HW Ong","year":"2023","unstructured":"Ong HW, Adderley J, Tobin AB, Drewry DH, Doerig C. Parasite and host kinases as targets for antimalarials. Expert Opin Ther Targets. 2023;27:151\u201369. https:\/\/doi.org\/10.1080\/14728222.2023.2185511.","journal-title":"Expert Opin Ther Targets"},{"issue":"21","key":"3000_CR92","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.3390\/molecules25215182","volume":"25","author":"C Moolman","year":"2020","unstructured":"Moolman C, Sluis RVD, Beteck RM, Legoabe LJ. An update on development of small-molecule plasmodial kinase inhibitors. Molecules. 2020;25:5182. https:\/\/doi.org\/10.3390\/molecules25215182.","journal-title":"Molecules"},{"key":"3000_CR93","doi-asserted-by":"publisher","first-page":"610408","DOI":"10.3389\/fmicb.2020.610408","volume":"11","author":"D Rotella","year":"2021","unstructured":"Rotella D, Siekierka J, Bhanot P. Plasmodium falciparum cGMP-dependent protein kinase\u2013a novel chemotherapeutic target. Front Microbiol. 2021;11:610408. https:\/\/doi.org\/10.3389\/fmicb.2020.610408.","journal-title":"Front Microbiol"},{"issue":"7479","key":"3000_CR94","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature12782","volume":"504","author":"CW McNamara","year":"2013","unstructured":"McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Nagle A, et al. Targeting Plasmodium PI (4) K to eliminate malaria. Nature. 2013;504:248\u201353. https:\/\/doi.org\/10.1038\/nature12782.","journal-title":"Nature"},{"issue":"4","key":"3000_CR95","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.01896-19","volume":"64","author":"P Sinxadi","year":"2020","unstructured":"Sinxadi P, Donini C, Johnstone H, Langdon G, Wiesner L, Allen E, et al. Safety, tolerability, pharmacokinetics, and antimalarial activity of the novel Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048 in healthy volunteers. Antimicrob Agents Chemother. 2020;64:10\u20131128. https:\/\/doi.org\/10.1128\/aac.01896-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3000_CR96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41467-017-00053-1","volume":"8","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kumar M, Ekka R, Dvorin JD, Paul AS, Madugundu AK, et al. PfCDPK1 mediated signaling in erythrocytic stages of Plasmodium falciparum. Nat Commun. 2017;8:63. https:\/\/doi.org\/10.1038\/s41467-017-00053-1.","journal-title":"Nat Commun"},{"issue":"4","key":"3000_CR97","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1073\/pnas.1715443115","volume":"115","author":"A Bansal","year":"2018","unstructured":"Bansal A, Molina-Cruz A, Brzostowski J, Liu P, Luo Y, Gunalan K, et al. Pf CDPK1 is critical for malaria parasite gametogenesis and mosquito infection. Proc Natl Acad Sci. 2018;115:774\u20139. https:\/\/doi.org\/10.1073\/pnas.1715443115.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"3000_CR98","doi-asserted-by":"publisher","first-page":"e02575","DOI":"10.1128\/mBio.02575-21","volume":"12","author":"S Kumar","year":"2021","unstructured":"Kumar S, Haile MT, Hoopmann MR, Tran LT, Michaels SA, Morrone SR, et al. Plasmodium falciparum calcium-dependent protein kinase 4 is critical for male gametogenesis and transmission to the mosquito vector. MBio. 2021;12:e02575\u201321. https:\/\/doi.org\/10.1128\/mBio.02575-21.","journal-title":"MBio"},{"key":"3000_CR99","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fimmu.2017.00349","volume":"8","author":"R Soni","year":"2017","unstructured":"Soni R, Sharma D, Rai P, Sharma B, Bhatt TK. Signaling strategies of malaria parasite for its survival, proliferation, and infection during erythrocytic stage. Front Immunol. 2017;8:349. https:\/\/doi.org\/10.3389\/fimmu.2017.00349.","journal-title":"Front Immunol"},{"issue":"1","key":"3000_CR100","doi-asserted-by":"publisher","first-page":"11930","DOI":"10.1038\/s41598-020-68717-5","volume":"10","author":"E Hitz","year":"2020","unstructured":"Hitz E, Balestra AC, Brochet M, Voss TS. PfMAP-2 is essential for male gametogenesis in the malaria parasite Plasmodium falciparum. Sci Rep. 2020;10:11930. https:\/\/doi.org\/10.1038\/s41598-020-68717-5.","journal-title":"Sci Rep"},{"key":"3000_CR101","doi-asserted-by":"crossref","unstructured":"Janha O, Olaniyan N, Diam GK, Sharma S, Beraldi D, Jamieson AG et al. Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates. Antimicrob Agents Chemother. 2026;e01561-25.","DOI":"10.1128\/aac.01561-25"},{"issue":"21","key":"3000_CR102","doi-asserted-by":"publisher","first-page":"18895","DOI":"10.1021\/acs.jmedchem.4c01300","volume":"67","author":"SB Brettell","year":"2024","unstructured":"Brettell SB, Janha O, Begen A, Cann G, Sharma S, Olaniyan N, et al. Targeting PfCLK3 with covalent inhibitors: a novel strategy for malaria treatment. J Med Chem. 2024;67:18895. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01300.","journal-title":"J Med Chem"},{"issue":"17","key":"3000_CR103","doi-asserted-by":"publisher","first-page":"9300","DOI":"10.1021\/acs.jmedchem.0c00451","volume":"63","author":"A Mahindra","year":"2020","unstructured":"Mahindra A, Janha O, Mapesa K, Sanchez-Azqueta A, Alam MM, Amambua-Ngwa A, et al. Development of potent PfCLK3 inhibitors based on TCMDC-135051 as a new class of antimalarials. J Med Chem. 2020;63:9300. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00451.","journal-title":"J Med Chem"},{"issue":"1","key":"3000_CR104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3831\/KPI.2016.19.001","volume":"19","author":"A Mukherjee","year":"2016","unstructured":"Mukherjee A, Sadhukhan GC. Anti-malarial drug design by targeting apicoplasts: new perspectives. J Pharmacopunct. 2016;19:7. https:\/\/doi.org\/10.3831\/KPI.2016.19.001.","journal-title":"J Pharmacopunct"},{"issue":"1","key":"3000_CR105","doi-asserted-by":"publisher","first-page":"9940468","DOI":"10.1155\/2024\/9940468","volume":"2024","author":"CO Mamudu","year":"2024","unstructured":"Mamudu CO, Tebamifor ME, Sule MO, Dokunmu TM, Ogunlana OO, Iheagwam FN. Apicoplast-resident processes: exploiting the chink in the armour of Plasmodium falciparum parasites. Adv Pharmacol Pharm Sci. 2024;2024:9940468. https:\/\/doi.org\/10.1155\/2024\/9940468.","journal-title":"Adv Pharmacol Pharm Sci"},{"issue":"42","key":"3000_CR106","doi-asserted-by":"publisher","first-page":"27630","DOI":"10.1021\/acsomega.1c01711","volume":"6","author":"MB Girma","year":"2021","unstructured":"Girma MB, Ball HS, Wang X, Brothers RC, Jackson ER, Meyers MJ, et al. Mechanism of action of N-Acyl and N-Alkoxy Fosmidomycin analogs: mono-and bisubstrate inhibition of IspC from Plasmodium falciparum, a causative agent of malaria. ACS omega. 2021;6:27630. https:\/\/doi.org\/10.1021\/acsomega.1c01711.","journal-title":"ACS omega"},{"issue":"10","key":"3000_CR107","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1096\/fj.11-187401","volume":"25","author":"EH Ekland","year":"2011","unstructured":"Ekland EH, Schneider J, Fidock DA. Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. FASEB J. 2011;25:3583. https:\/\/doi.org\/10.1096\/fj.11-187401.","journal-title":"FASEB J"},{"issue":"5","key":"3000_CR108","doi-asserted-by":"publisher","first-page":"107112","DOI":"10.1016\/j.ijantimicag.2024.107112","volume":"63","author":"N Amanzougaghene","year":"2024","unstructured":"Amanzougaghene N, Tajeri S, Franetich JF, Ashraf K, Soulard V, Bigeard P, et al. Azithromycin disrupts apicoplast biogenesis in replicating and dormant liver stages of the relapsing malaria parasites Plasmodium vivax and Plasmodium cynomolgi. Int J Antimicrob Agents. 2024;63:107112. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107112.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"3000_CR109","doi-asserted-by":"publisher","first-page":"e2005895","DOI":"10.1371\/journal.pbio.2005895","volume":"16","author":"MJ Boucher","year":"2018","unstructured":"Boucher MJ, Ghosh S, Zhang L, Lal A, Jang SW, Ju A, et al. Integrative proteomics and bioinformatic prediction enable a high-confidence apicoplast proteome in malaria parasites. PLoS Biol. 2018;16:e2005895. https:\/\/doi.org\/10.1371\/journal.pbio.2005895.","journal-title":"PLoS Biol"},{"issue":"7","key":"3000_CR110","doi-asserted-by":"publisher","first-page":"e3000376","DOI":"10.1371\/journal.pbio.3000376","volume":"17","author":"K Kennedy","year":"2019","unstructured":"Kennedy K, Cobbold SA, Hanssen E, Birnbaum J, Spillman NJ, McHugh E, et al. Delayed death in the malaria parasite Plasmodium falciparum is caused by disruption of prenylation-dependent intracellular trafficking. PLoS Biol. 2019;17:e3000376. https:\/\/doi.org\/10.1371\/journal.pbio.3000376.","journal-title":"PLoS Biol"},{"issue":"2","key":"3000_CR111","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1128\/EC.00198-14","volume":"14","author":"JD Wiley","year":"2015","unstructured":"Wiley JD, Merino EF, Krai PM, McLean KJ, Tripathi AK, Vega-Rodr\u00edguez J, et al. Isoprenoid precursor biosynthesis is the essential metabolic role of the apicoplast during gametocytogenesis in Plasmodium falciparum. Eukaryot Cell. 2015;14:128\u201339. https:\/\/doi.org\/10.1128\/EC.00198-14.","journal-title":"Eukaryot Cell"},{"issue":"9","key":"3000_CR112","doi-asserted-by":"publisher","first-page":"e1010803","DOI":"10.1371\/journal.ppat.1010803","volume":"18","author":"AJ Jezewski","year":"2022","unstructured":"Jezewski AJ, Guggisberg AM, Hodge DM, Ghebremichael N, John GN, McLellan LK, John O, A. R. GAPDH mediates drug resistance and metabolism in Plasmodium falciparum malaria parasites. PLoS Pathog. 2022;18:e1010803. https:\/\/doi.org\/10.1371\/journal.ppat.1010803.","journal-title":"PLoS Pathog"},{"issue":"11","key":"3000_CR113","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2174\/138161207780618939","volume":"13","author":"N Singh","year":"2007","unstructured":"Singh N, Cheve G, Avery MA, McCurdy CR. Targeting the methyl erythritol phosphate (MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme. Curr Pharm Design. 2007;13:1161\u201377. https:\/\/doi.org\/10.2174\/138161207780618939.","journal-title":"Curr Pharm Design"},{"issue":"3","key":"3000_CR114","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1021\/acsinfecdis.3c00670","volume":"10","author":"S Johannsen","year":"2024","unstructured":"Johannsen S, Gierse RM, Kru\u0308ger A, Edwards RL, Nanna V, Fontana A, Hirsch AK. High target homology does not guarantee inhibition: Aminothiazoles emerge as inhibitors of plasmodium falciparum. ACS Infect Dis. 2024;10(3):1000\u201322. https:\/\/doi.org\/10.1021\/acsinfecdis.3c00670","journal-title":"ACS Infect Dis"},{"issue":"1","key":"3000_CR115","doi-asserted-by":"publisher","first-page":"8400","DOI":"10.1038\/s41598-017-07159-y","volume":"7","author":"RL Edwards","year":"2017","unstructured":"Edwards RL, Brothers RC, Wang X, Maron MI, Ziniel PD, Tsang PS, et al. MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis. Sci Rep. 2017;7:8400. https:\/\/doi.org\/10.1038\/s41598-017-07159-y.","journal-title":"Sci Rep"},{"issue":"1","key":"3000_CR116","doi-asserted-by":"publisher","first-page":"e1011557","DOI":"10.1371\/journal.ppat.1011557","volume":"20","author":"M Crispim","year":"2024","unstructured":"Crispim M, Verdaguer IB, Hern\u00e1ndez A, Kronenberger T, Fenollar \u00c0, Yamaguchi LF, et al. Beyond the MEP pathway: a novel kinase required for prenol utilization by malaria parasites. PLoS Pathog. 2024;20:e1011557. https:\/\/doi.org\/10.1371\/journal.ppat.1011557.","journal-title":"PLoS Pathog"},{"issue":"8","key":"3000_CR117","doi-asserted-by":"publisher","first-page":"e01238","DOI":"10.1128\/aac.01238-23","volume":"68","author":"S Kabeche","year":"2024","unstructured":"Kabeche S, Braukmann T, Doenier J, Meister T, Yeh E. A picomolar inhibitor of the Plasmodium falciparum IPP pathway. Antimicrob Agents Chemother. 2024;68:e01238\u201323. https:\/\/doi.org\/10.1128\/aac.01238-23.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3000_CR118","doi-asserted-by":"publisher","first-page":"657189","DOI":"10.1155\/2014\/657189","volume":"2014","author":"T Qidwai","year":"2014","unstructured":"Qidwai T, Jamal F, Khan MY, Sharma B. [Retracted] Exploring drug targets in isoprenoid biosynthetic pathway for Plasmodium falciparum. Biochem Res Int. 2014;2014:657189. https:\/\/doi.org\/10.1155\/2014\/657189.","journal-title":"Biochem Res Int"},{"key":"3000_CR119","doi-asserted-by":"publisher","first-page":"1035548","DOI":"10.3389\/fchem.2022.1035548","volume":"10","author":"I Bofill Verdaguer","year":"2022","unstructured":"Bofill Verdaguer I, Sussmann RA, Santiago VF, Palmisano G, Moura GC, Mesquita JT, et al. Isoprenoid alcohols utilization by malaria parasites. Front Chem. 2022;10:1035548. https:\/\/doi.org\/10.3389\/fchem.2022.1035548.","journal-title":"Front Chem"},{"key":"3000_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110726","author":"OA Akuh","year":"2025","unstructured":"Akuh OA, Maus D, Blume M, Saliba KJ, Seeber F Reconstituted ferredoxin\u2013MEP pathway of Apicomplexa in Escherichia coli as an in situ screening platform for inhibitors and essential enzyme mutations. J Biol Chem. 2025. https:\/\/doi.org\/10.1016\/j.jbc.2025.110726.","journal-title":"J Biol Chem"},{"issue":"5","key":"3000_CR121","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1042\/BST20200224","volume":"48","author":"PP Calic","year":"2020","unstructured":"Calic PP, Mansouri M, Scammells PJ, McGowan S. Driving antimalarial design through understanding of target mechanism. Biochem Soc Trans. 2020;48:2067\u201378. https:\/\/doi.org\/10.1042\/BST20200224.","journal-title":"Biochem Soc Trans"},{"issue":"7","key":"3000_CR122","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s42452-020-2955-1","volume":"2","author":"ZYU Ibrahim","year":"2020","unstructured":"Ibrahim ZYU, Uzairu A, Shallangwa G, Abechi S. QSAR and molecular docking based design of some indolyl-3-ethanone-\u03b1-thioethers derivatives as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors: ZY Ibrahim et al. SN Appl Sci. 2020;2:1170. https:\/\/doi.org\/10.1007\/s42452-020-2955-1.","journal-title":"SN Appl Sci"},{"issue":"11","key":"3000_CR123","doi-asserted-by":"publisher","first-page":"e00459","DOI":"10.1128\/aac.00459-25","volume":"69","author":"S Taweechai","year":"2025","unstructured":"Taweechai S, Tota\u00f1es FIG, Westhead D, Herrera-Arozamena C, Foster R, McConkey GA. Validated antimalarial drug target discovery using genome-scale metabolic modeling. Antimicrob Agents Chemother. 2025;69:e00459\u201325. https:\/\/doi.org\/10.1128\/aac.00459-25.","journal-title":"Antimicrob Agents Chemother"},{"key":"3000_CR124","unstructured":"VT Y. Purine and pyrimidine pathways as antimalarial targets. Malaria. 2023;187."},{"issue":"41","key":"3000_CR125","doi-asserted-by":"publisher","first-page":"19070","DOI":"10.1021\/jacs.2c08128","volume":"144","author":"C Wang","year":"2022","unstructured":"Wang C, Zhang B, Kruger A, Du X, Visser L, Domling AS, et al. Discovery of small-molecule allosteric inhibitors of PfATC as antimalarials. J Am Chem Soc. 2022;144:19070\u20137. https:\/\/doi.org\/10.1021\/jacs.2c08128.","journal-title":"J Am Chem Soc"},{"issue":"13","key":"3000_CR126","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3390\/ijms22137236","volume":"22","author":"ED Hartuti","year":"2021","unstructured":"Hartuti ED, Sakura T, Tagod MS, Yoshida E, Wang X, Mochizuki K, et al. Identification of 3, 4-Dihydro-2 H, 6 H-pyrimido [1, 2-c][1, 3] benzothiazin-6-imine derivatives as Novel Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase. Int J Mol Sci. 2021;22:7236. https:\/\/doi.org\/10.3390\/ijms22137236.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3000_CR127","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01837-18","volume":"63","author":"KA Collins","year":"2019","unstructured":"Collins KA, R\u00fcckle T, Elliott S, Marquart L, Ballard E, Chalon S, et al. DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum. Antimicrob Agents Chemother. 2019;63:10\u20131128. https:\/\/doi.org\/10.1128\/AAC.01837-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"3000_CR128","doi-asserted-by":"publisher","first-page":"1773050","DOI":"10.3389\/fmicb.2026.1773050","volume":"17","author":"W Tashie","year":"2026","unstructured":"Tashie W, De Koning HP, Duah-Quashie NO, Quashie NB. Targeting Plasmodium falciparum with purine antimetabolites as a therapeutic strategy. Front Microbiol. 2026;17:1773050. https:\/\/doi.org\/10.3389\/fmicb.2026.1773050.","journal-title":"Front Microbiol"},{"key":"3000_CR129","doi-asserted-by":"publisher","first-page":"1374735","DOI":"10.3389\/fcell.2024.1374735","volume":"12","author":"AG Adegboro","year":"2024","unstructured":"Adegboro AG, Afolabi IS. Molecular mechanisms of mitochondria-mediated ferroptosis: a potential target for antimalarial interventions. Front Cell Dev Biology. 2024;12:1374735. https:\/\/doi.org\/10.3389\/fcell.2024.1374735.","journal-title":"Front Cell Dev Biology"},{"issue":"18","key":"3000_CR130","doi-asserted-by":"publisher","first-page":"9150","DOI":"10.3390\/ijms26189150","volume":"26","author":"S Greco","year":"2025","unstructured":"Greco S, Assalve G, Lunetti P, Kayentao K, Dara A, Scaramuzzi D, et al. Targeting mitochondrial function in plasmodium falciparum: insight into antimalarial drugs and the emerging role of Saccharomyces cerevisiae as a model system. Int J Mol Sci. 2025;26:9150. https:\/\/doi.org\/10.3390\/ijms26189150.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3000_CR131","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1021\/acs.jmedchem.6b01733","volume":"60","author":"Y Yang","year":"2017","unstructured":"Yang Y, Yu Y, Li X, Li J, Wu Y, Yu J, et al. Target elucidation by cocrystal structures of NADH-ubiquinone oxidoreductase of Plasmodium falciparum (Pf NDH2) with small molecule to eliminate drug-resistant malaria. J Med Chem. 2017;60:1994\u20132005. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01733.","journal-title":"J Med Chem"},{"issue":"6","key":"3000_CR132","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/genes10060471","volume":"10","author":"X Wang","year":"2019","unstructured":"Wang X, Miyazaki Y, Inaoka DK, Hartuti ED, Watanabe YI, Shiba T, et al. Identification of Plasmodium falciparum mitochondrial malate: quinone oxidoreductase inhibitors from the pathogen box. Genes. 2019;10:471. https:\/\/doi.org\/10.3390\/genes10060471.","journal-title":"Genes"},{"issue":"12","key":"3000_CR133","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1021\/acsmedchemlett.8b00371","volume":"9","author":"D Hong","year":"2018","unstructured":"Hong D, Leung W, Amporndanai SC, Davies K, Priestley J, Nixon RS, G. L., et al. Potent antimalarial 2-Pyrazolyl Quinolone bc 1 (Qi) inhibitors with improved drug-like properties. ACS Med Chem Lett. 2018;9:1205\u201310. https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00371.","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"3000_CR134","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1128\/AAC.01183-15","volume":"59","author":"GP Miley","year":"2015","unstructured":"Miley GP, Pou S, Winter R, Nilsen A, Li Y, Kelly JX, et al. ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria. Antimicrob Agents Chemother. 2015;59:5555\u201360. https:\/\/doi.org\/10.1128\/AAC.01183-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"3000_CR135","doi-asserted-by":"publisher","first-page":"e110041","DOI":"10.1371\/journal.pone.0110041","volume":"9","author":"BA Akhoon","year":"2014","unstructured":"Akhoon BA, Singh KP, Varshney M, Gupta SK, Shukla Y, Gupta SK. Understanding the mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation Y268S using computational methods. PLoS ONE. 2014;9:e110041. https:\/\/doi.org\/10.1371\/journal.pone.0110041.","journal-title":"PLoS ONE"},{"issue":"3","key":"3000_CR136","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0035-9203(03)90162-3","volume":"97","author":"MM Thapar","year":"2003","unstructured":"Thapar MM, Gupta S, Spindler C, Wernsdorfer WH, Bj\u00f6rkman A. Pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg. 2003;97:331\u20137. https:\/\/doi.org\/10.1016\/S0035-9203(03)90162-3.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"51","key":"3000_CR137","doi-asserted-by":"publisher","first-page":"eadq6651","DOI":"10.1126\/sciadv.adq6651","volume":"10","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Lyu M, Han X, Bandara S, Cui M, Istvan ES, et al. The Plasmodium falciparum NCR1 transporter is an antimalarial target that exports cholesterol from the parasite\u2019s plasma membrane. Sci Adv. 2024;10:eadq6651. https:\/\/doi.org\/10.1126\/sciadv.adq6651.","journal-title":"Sci Adv"},{"key":"3000_CR138","doi-asserted-by":"publisher","first-page":"984049","DOI":"10.3389\/fcimb.2022.984049","volume":"12","author":"AG Maier","year":"2022","unstructured":"Maier AG, van Ooij C. The role of cholesterol in invasion and growth of malaria parasites. Front Cell Infect Microbiol. 2022;12:984049. https:\/\/doi.org\/10.3389\/fcimb.2022.984049.","journal-title":"Front Cell Infect Microbiol"},{"key":"3000_CR139","doi-asserted-by":"publisher","first-page":"e40529","DOI":"10.7554\/eLife.40529","volume":"8","author":"ES Istvan","year":"2019","unstructured":"Istvan ES, Das S, Bhatnagar S, Beck JR, Owen E, Llinas M, et al. Plasmodium Niemann-Pick type C1-related protein is a druggable target required for parasite membrane homeostasis. Elife. 2019;8:e40529. https:\/\/doi.org\/10.7554\/eLife.40529.","journal-title":"Elife"},{"issue":"4","key":"3000_CR140","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/17460441.2020.1704251","volume":"15","author":"HH Nguyen","year":"2020","unstructured":"Nguyen HH, Yeoh LM, Chisholm SA, Duffy MF. Developments in drug design strategies for bromodomain protein inhibitors to target Plasmodium falciparum parasites. Expert Opin Drug Discov. 2020;15:415\u201325. https:\/\/doi.org\/10.1080\/17460441.2020.1704251.","journal-title":"Expert Opin Drug Discov"},{"key":"3000_CR141","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ijbiomac.2022.10.247","volume":"223","author":"AK Singh","year":"2022","unstructured":"Singh AK, Phillips M, Alkrimi S, Tonelli M, Boyson SP, Malone KL, et al. Structural insights into acetylated histone ligand recognition by the BDP1 bromodomain of Plasmodium falciparum. Int J Biol Macromol. 2022;223:316\u201326. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.10.247.","journal-title":"Int J Biol Macromol"},{"key":"3000_CR142","doi-asserted-by":"publisher","first-page":"816558","DOI":"10.3389\/fcell.2022.816558","volume":"10","author":"JE Quinn","year":"2022","unstructured":"Quinn JE, Jeninga MD, Limm K, Pareek K, Mei\u00dfgeier T, Bachmann A, et al. The putative bromodomain protein PfBDP7 of the human malaria parasite Plasmodium falciparum cooperates with PfBDP1 in the silencing of variant surface antigen expression. Front Cell Dev Biology. 2022;10:816558. https:\/\/doi.org\/10.3389\/fcell.2022.816558.","journal-title":"Front Cell Dev Biology"},{"issue":"11","key":"3000_CR143","doi-asserted-by":"publisher","first-page":"e202500024","DOI":"10.1002\/cmdc.202500024","volume":"20","author":"M Amann","year":"2025","unstructured":"Amann M, Warstat R, Rechten KK, Theuer P, Schustereder M, Clavey S, et al. A novel inhibitor against the Bromodomain Protein 1 of the malaria pathogen Plasmodium falciparum. ChemMedChem. 2025;20:e202500024. https:\/\/doi.org\/10.1002\/cmdc.202500024.","journal-title":"ChemMedChem"},{"issue":"1","key":"3000_CR144","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1038\/s41467-026-70280-y","volume":"17","author":"CP Sanchez","year":"2026","unstructured":"Sanchez CP, Duffey M, Celada RV, Kucharski M, Hoarau M, Saeyang T, et al. Mechanisms of PfDNMT2 inhibition and PfATP6-mediated resistance to the antimalarial candidate SC83288 in Plasmodium falciparum. Nat Commun. 2026;17:2327. https:\/\/doi.org\/10.1038\/s41467-026-70280-y.","journal-title":"Nat Commun"},{"issue":"2","key":"3000_CR145","doi-asserted-by":"publisher","first-page":"e31847","DOI":"10.1371\/journal.pone.0031847","volume":"7","author":"KT Andrews","year":"2012","unstructured":"Andrews KT, Gupta AP, Tran TN, Fairlie DP, Gobert GN, Bozdech Z. Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors. PLoS ONE. 2012;7:e31847. https:\/\/doi.org\/10.1371\/journal.pone.0031847.","journal-title":"PLoS ONE"},{"issue":"10","key":"3000_CR146","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3390\/pharmaceutics15102440","volume":"15","author":"T Reyser","year":"2023","unstructured":"Reyser T, Paloque L, Nguyen M, Augereau JM, Fuchter MJ, Lopez M, et al. Epidrugs as promising tools to eliminate Plasmodium falciparum artemisinin-resistant and quiescent parasites. Pharmaceutics. 2023;15:2440. https:\/\/doi.org\/10.3390\/pharmaceutics15102440.","journal-title":"Pharmaceutics"},{"issue":"11","key":"3000_CR147","doi-asserted-by":"publisher","first-page":"e00420","DOI":"10.1128\/aac.00420-22","volume":"66","author":"A Nurkanto","year":"2022","unstructured":"Nurkanto A, Imamura R, Rahmawati Y, Prabandari EE, Waluyo D, Annoura T, et al. Dephospho-coenzyme A kinase is an exploitable drug target against Plasmodium falciparum: identification of selective inhibitors by high-throughput screening of a large chemical compound library. Antimicrob Agents Chemother. 2022;66:e00420\u201322. https:\/\/doi.org\/10.1128\/aac.00420-22.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3000_CR148","doi-asserted-by":"publisher","first-page":"105573","DOI":"10.1016\/j.arabjc.2023.105573","volume":"17","author":"GP Adebayo","year":"2024","unstructured":"Adebayo GP, Oduselu GO, Aderohunmu DV, Klika KD, Olasehinde GI, Ajani OO, Adebiyi E. Structure-based design, and development of amidinyl, amidoximyl and hydroxamic acid based organic molecules as novel antimalarial drug candidates. Arab J Chem. 2024;17:105573. https:\/\/doi.org\/10.1016\/j.arabjc.2023.105573.","journal-title":"Arab J Chem"},{"key":"3000_CR149","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3389\/fphar.2019.01526","volume":"10","author":"A Keshavarzi Arshadi","year":"2020","unstructured":"Keshavarzi Arshadi A, Salem M, Collins J, Yuan JS, Chakrabarti D. DeepMalaria: artificial intelligence driven discovery of potent antiplasmodials. Front Pharmacol. 2020;10:1526. https:\/\/doi.org\/10.3389\/fphar.2019.01526.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3000_CR150","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1038\/s41467-022-33379-6","volume":"13","author":"KT Ko","year":"2022","unstructured":"Ko KT, Lennartz F, Mekhaiel D, Guloglu B, Marini A, Deuker DJ, et al. Structure of the malaria vaccine candidate Pfs48\/45 and its recognition by transmission blocking antibodies. Nat Commun. 2022;13:5603. https:\/\/doi.org\/10.1038\/s41467-022-33379-6.","journal-title":"Nat Commun"},{"issue":"D1","key":"3000_CR151","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022;50:D439\u201344. https:\/\/doi.org\/10.1093\/nar\/gkab1061.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3000_CR152","doi-asserted-by":"publisher","first-page":"10527","DOI":"10.1038\/s41598-024-60058-x","volume":"14","author":"HM Behrens","year":"2024","unstructured":"Behrens HM, Spielmann T. Identification of domains in Plasmodium falciparum proteins of unknown function using DALI search on AlphaFold predictions. Sci Rep. 2024;14:10527. https:\/\/doi.org\/10.1038\/s41598-024-60058-x.","journal-title":"Sci Rep"},{"issue":"11","key":"3000_CR153","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/pathogens11111271","volume":"11","author":"H Yan","year":"2022","unstructured":"Yan H, Feng J, Chen M. Structural modelling prediction of recombinant Plasmodium falciparum K13-F446I and K13-C580Y gene by AlphaFold method and heterologous expression in Spodoptera frugiperda 9 cells. Pathogens. 2022;11:1271. https:\/\/doi.org\/10.3390\/pathogens11111271.","journal-title":"Pathogens"},{"issue":"5","key":"3000_CR154","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1021\/acs.biochem.2c00669","volume":"62","author":"A Willems","year":"2023","unstructured":"Willems A, Kalaw A, Ecer A, Kotwal A, Roepe LD, Roepe PD. Structures of Plasmodium falciparum chloroquine resistance transporter (PfCRT) isoforms and their interactions with chloroquine. Biochemistry. 2023;62:1093. https:\/\/doi.org\/10.1021\/acs.biochem.2c00669.","journal-title":"Biochemistry"},{"issue":"1","key":"3000_CR155","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","volume":"26","author":"D Paul","year":"2021","unstructured":"Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discovery Today. 2021;26:80\u201393. https:\/\/doi.org\/10.1016\/j.drudis.2020.10.010","journal-title":"Drug Discovery Today"},{"issue":"1","key":"3000_CR156","doi-asserted-by":"publisher","first-page":"2634576","DOI":"10.1080\/26895293.2026.2634576","volume":"19","author":"E Chikwaro","year":"2026","unstructured":"Chikwaro E, Nyoni S, Ndlovu J, Shoko R. Natural products in antimalarial drug discovery: progress, emerging technologies, and future directions. All Life. 2026;19:2634576. https:\/\/doi.org\/10.1080\/26895293.2026.2634576.","journal-title":"All Life"},{"issue":"11","key":"3000_CR157","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1038\/s41594-025-01632-3","volume":"32","author":"L Anton","year":"2025","unstructured":"Anton L, Cheng W, Haile MT, Dziekan JM, Cobb DW, Zhu X, et al. Integrated structural biology of the native malarial translation machinery and its inhibition by an antimalarial drug. Nat Struct Mol Biol. 2025;32:2158\u201364. https:\/\/doi.org\/10.1038\/s41594-025-01632-3.","journal-title":"Nat Struct Mol Biol"},{"key":"3000_CR158","doi-asserted-by":"publisher","first-page":"1688455","DOI":"10.3389\/fmolb.2025.1688455","volume":"12","author":"G Jeyaraj","year":"2025","unstructured":"Jeyaraj G, Rajendran AK, Sathishkumar K, Almutairi BO, Vadivelu A, Chokkakula S, et al. High-resolution protein modeling through Cryo-EM and AI: current trends and future perspectives\u2013a review. Front Mol Biosci. 2025;12:1688455. https:\/\/doi.org\/10.3389\/fmolb.2025.1688455.","journal-title":"Front Mol Biosci"},{"key":"3000_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100423","author":"L Wei","year":"2021","unstructured":"Wei L, Adderley J, Leroy D, Drewry DH, Wilson DW, Kaushansky A, Doerig C Host-directed therapy, an untapped opportunity for antimalarial intervention. Cell Rep Med. 2021. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100423.","journal-title":"Cell Rep Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-03000-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-03000-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-03000-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:03:01Z","timestamp":1792537381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-03000-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":159,"alternative-id":["3000"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-03000-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human\/animal studies were involved in the present study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}